Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
  • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
  • C07D495/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/40—Oxygen atoms
  • C07D211/44—Oxygen atoms attached in position 4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
  • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
  • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
  • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D211/56—Nitrogen atoms
  • C07D211/58—Nitrogen atoms attached in position 4
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
  • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
  • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
  • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D333/66—Nitrogen atoms not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
  • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).
• diseases in particular viral diseases, in particular hepatitis C virus (HCV).
• HCV hepatitis C virus
• HCV liver transplantation
• HCV is an enveloped, positive-stranded RNA virus, member of the Flaviviridae family in the hepacivirus genus.
• HCV is closely related to the flavivirus genus, which includes a number of viruses implicated in human disease, such as dengue virus and yellow fever virus [2] .
• Seven major HCV genotypes and numerous subtypes have been described, which differ as much as -30% in the nucleotide sequences [3, 4].
• the single stranded 9.6 kb genome consists of a single open reading frame (ORF) which is flanked at the 5 ' and 3 ' ends by highly structured and conserved non-translated regions (NTRs) important for both viral translation and viral replication [5].
• NTRs non-translated regions
• the approximately 340 nucleotide long NTR sequence contains an internal ribosome entry site (IRES) that directs translation independent of a capstructure.
• IRS internal ribosome entry site
• the viral polyprotein is co- and posttranslationally processed into ten viral proteins (core, El, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).
• the HCV 5 'NTR and its IRES are characterized by the formation of complexes with the host cell small ribosomal subunit (40 S) and eukaryotic initiation factor (elF), resulting in the recognition of the viral start codon, thus starting the viral protein synthesis [6] .
• S small ribosomal subunit
• elF eukaryotic initiation factor
• HCV subgenomic replicons consist of a HCV RNA in which the HCV structural region is replaced by the neomycin phosphotransferase gene and translation of the viral proteins NS3 to NS5 is directed by the encephalomyocarditis virus (EMCV) IRES element flanked by the 5 ' and 3' NTRs.
• EMCV encephalomyocarditis virus
• Stable HCV RNA replication has been established in various liver and non-liver, human and non-human cell lines which are excellent tools to study the HCV life cycle and to validate novel antivirals [12, 15-17].
• Formula I compounds and Formula II compounds in accordance with the present invention have been found to possess useful activity against all major HCV genotypes. Additionally, compounds in accordance with the present invention have been shown to have significant antiviral activity against drug resistant viruses (protease, NS5A and polymerase).
• M molar
• mM millimolar
• ⁇ micromolar
• nM nanomolar
• pM picomolar
• nm nanometer
• mm millimeter
• wt weight
• N Normal
• CFU colony forming units
• i.v. intravenous
• Hz Hertz
• Tr retention time
• RP reverse phase
• TEA triethlamine
• TFA trifluoroacetic acid
• TFAA trifluoroacetic anhydride
• THF tetrahydrofuran
• DMSO dimethylsulf oxide
• EtOAc ethyl acetate
• DME (1,2-dimethoxyethane); DCM (dichloromethane);
• DCE dichloroethane
• DMF N,N-dimethylformamide
• DMPU N,N '-dimethylpropyleneurea
• CDI 1,1-carbonyldiimidazole
• IBCF isobutyl chloroformate
• AcOH acetic acid
• THP tetrahydropyran
• NMM N-methylmorpholine
• HOBT 1-hydroxybenzotriazole
• mCPBA metal-chloroperbenzoic acid
• EDC l-[3-dimethylamino] propyl-3-ei diimide hydrochloride
• DCC dicyclohexylcarbodiimide
• CBZ benzyloxycarbonyl
• Ac acetyl
• atm atmosphere
• TMSE (2-(trimethylsilyl)ethyl); TMS (trimethylsilyl); TIPS (triisopropylsilyl); TBS (i-butyldimethylsilyl);
• DMAP 4-dimethylaminopyridine
• BSA bovine serum albumin
• NAD nicotinamide adenine dinucleotide
• HPLC high pressure chromatography
• LC/MS liquid chromatography/mass spectrometry
• BOP bis(2-oxo-3-oxazolidinyl)phosphinic chloride
• TBAF tetra-w-butylammonium fluoride
• HBTU O-benzotriazole- l-yl-N,N,N',N'-tetramethyluroniumhexafluoro phosphate
• HEPES 4-(2-hydroxyethyl)-l-piperazine ethane sulfonic acid
• DPPA diphenylphosphoryl azide
• LAH Lithium aluminum hydride
• NaOMe sodium methoxide
• EDTA ethylenediaminetetraacetic acid
• TMED A ( ⁇ , ⁇ , ⁇ ' ,N ' -tetramethyl- 1 ,2-ethanediamine) ;
• NB S N-bromo succinimide
• DIPEA diisopropylethylamine
• Dppf (1 , 1 '-bis(diphenylphosphino)ferrocene); and NIS (N-iodosuccinimide).
• Alkyl refers to a monovalent saturated hydrocarbon chain having the specified number of member carbon atoms.
• C1-C7 alkyl refers to an alkyl group having from 1 to 7 member carbon atoms.
• Alkyl groups may be optionally substituted with one or more substituents with one or more substituents as defined herein.
• Alkyl groups may be straight or branched. Representative branched alkyl groups have one, two, or three branches.
• alkyl refers to Ci, C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 , C n , C 12 , C 13 , C 14 , C 15 , C 16 C 17 , Ci 8 , Ci 9 , C 2 o, C 21 , C 22 , C 23 and/or C 24 , alkyl, and combinations of any of the foregoing including the ranges Q to C 4 , alkyl, C 2 - C 4 alkyl, C 2 - C 12 alkyl, C 3 - C 6 alkyl, C 3 - C 12 alkyl, C 4 - C 6 alkyl, C 4 - Cg alkyl, C 4 - C 10 alkyl, C 4 - C 12 alkyl, C 5 - Cg alkyl, C 5 - C 10 alkyl, C 5 - C 12 alkyl, C 5 - C 14 alkyl, C
• Alkenyl refers to an unsaturated hydrocarbon chain having the specified number of member carbon atoms and having one or more carbon-carbon double bonds within the chain.
• C2-C6 alkenyl refers to an alkenyl group having from 2 to 6 member carbon atoms.
• alkenyl groups have one carbon-carbon double bond within the chain.
• alkenyl groups have more than one carbon-carbon double bond within the chain.
• Alkenyl groups may be optionally substituted with one or more substituents as defined herein. Alkenyl groups may be straight or branched.
• alkenyl useful in accordance with the present invention are C 2 - C 10 , C 2 - C 9 , C 2 - Cg, C 2 - C 7 , C 2 - C 6 , C 2 - C 5 and C 2 - C 4 alkenyl.
• Alkoxy refers to an alkyl moiety attached through an oxygen bridge (i.e. a -0-C1-C6 alkyl group wherein C1-C6 is defined herein). Examples of such groups include methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.
• Alkynyl refers to an unsaturated hydrocarbon chain having the specified number of member carbon atoms and having one or more carbon-carbon ripple bonds within the chain.
• C2-C6 alkynyl refers to an alkynyl group having from 2 to 6 member atoms. Alkynyl groups may be optionally substituted with one or more substituents. Examples of alkynyls useful in accordance with the present invention are C 2 - C 10 , C 2 - C 9 , C 2 - Cg, C 2 - C 7 , C 2 - C 6 , C 2 - C 5 and C 2 - C 4 alkynyl.
• Aryl refers to an aromatic hydrocarbon ring system.
• Aryl groups are monocyclic ring systems or bicyclic ring systems.
• Monocyclic aryl ring refers to phenyl.
• Bicyclic aryl rings refer to naphthyl and to rings wherein phenyl is fused to a cycloalkyl or cycloalkenyl ring having 5,6, or 7 member carbon atoms.
• Aryl groups may be optionally substituted with one or more substituents as defined herein.
• substituents that are suitable include but are not limited to hydroxyl, halogen, cyano, sulfonyl, further aryl(s), Ci - C 5 alkyl, Ci - C 4 alkoxy, oxo, C 3 - C 6 cycloalkyl, heteroaryl, heterocycloalkyl, Q - C 3 sulfanyl.
• 'Cycloalkyl refers to a saturated hydrocarbon ring having the specified number of member carbon atoms. Cycloalkyl groups are monocyclic ring systems.
• C3-C7 cycloalkyl refers to a cycloalkyl group having from 3 to 6 member atoms.
• Cycloalkyl groups may be optionally substituted with one or more substituents as defined herein.
• Cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
• substituents that are suitable include but are not limited to hydroxyl, halogen, cyano, sulfonyl, further aryl(s), Ci - C 5 alkyl, Ci - C 4 alkoxy, oxo, C 3 - C 6 cycloalkyl, heteroaryl, heterocycloalkyl, Ci - C 3 sulfanyl.
• Boc refers to tert-butyloxycarbonyl.
• Cycloalkenyl refers to an unsaturated carbon ring having the specified number of member carbon atoms and having a carbon-carbon double bond within the ring.
• C3-C6 cycloalkenyl refers to a cycloalkenyl group having from 3 to 6 member carbon atoms.
• Cycloalkenyl rings are not aromatic.
• Cycloalkenyl groups are monocyclic ring systems. Cycloalkenyl groups may be optionally substituted with one or more substituents as defined herein.
• Halo refers to the halogen radicals fluoro, chloro, bromo, and iodo.
• Haloalkyl refers to an alkyl group wherein at least one hydrogen atom attached to a member atom within the alkyl group is replaced with halo.
• the number of halo substituents include but are not limited to 1, 2, 3, 4, 5, or 6 substituents.
• Haloalkyl includes monofluoromethyl, difluoroethyl, and trifluoromethyl.
• Heteroaryl refers to an aromatic ring containing from 1 to 5, suitably 1 to 4, more suitably 1 or 2 heteroatoms as member atoms in the ring. Heteroaryl groups containing more than one heteroatom may contain different heteroatoms. Heteroaryl groups may be optionally substituted with one or more substituents as defined herein. Heteroaryl groups are monocyclic ring systems, or fused bicyclic ring systems. Monocyclic heteroaryl rings have from 5 to 6 member atoms. Bicyclic heteroaryl rings have from 8 to 10 member atoms.
• Bicylic heteroaryl rings include those rings wherein the primary heteroaryl and the secondary monocyclic cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl ring are attached, forming a fused bicyclic ring system.
• Heteroaryl includes, among others, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furanyl, furazanyl, thienyl, triazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, tetrazinyl, tetrazolyl, indolyl, isoindolyl, indolizinyl, indazolyl, purinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pteridinyl, cinnolinyl, benzimidazolyl, benzopyranyl, benzoxazolyl, benzisoazolyl, benzofuranyl
• Heteroatom refers to a nitrogen, sulfur, or oxygen atom.
• Heterocycloalkyl refers to a saturated or unsaturated ring containing from 1 to 4 heteroatoms as member atoms in the ring. Heterocycloalkyl rings are not aromatic. Heterocycloalkyl groups containing more than one heteroatom may contain different heteroatoms. Heterocycloalkyl groups may be optionally substituted with one or more substituents as defined herein. Heterocycloalkyl groups are monocyclic ring systems or are fused, spiro, or bridged bicyclic ring systems. Monocyclic heterocycloalkyl rings have from 4 to 7 member atoms. Bicyclic heterocycloalkyl rings have from 7 to 11 member atoms.
• Member atoms refers to the atom or atoms that form a chain or ring. Where more than one member atom is present in a chain and within a ring, each member atom is covalently bound to an adjacent member atom in the chain or ring. Atoms that make up a substituent group on a chain or ring are no member atoms in the chain or ring.
• Optionally substituted indicates that a group, such as alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heteroaryl, may be unsubstituted, or the group may be substituted with one or more substituents as defined herein.
• “Pharmaceutically acceptable” refers to those compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings or animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• Substituted in reference to a group indicates that one or more hydrogen atoms attached to a member atom within the group is replaced with a substituent selected from the group of defined or suitable substituents. It should be understood that the term “substituted” includes the implicit provision that such substitution be in accordance with the permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound. When it is stated that a group may contain one or more substituents, one or more member atom within the group may be substituted. In addition, a single member atom within the group may be substituted with more than one substituent as long as such substitution is in accordance with the permitted valence of the atom.
• the present invention is directed to compounds according to Formula I:
• U is an aryl or heteroaryl; preferably a thiophene or phenyl;
• W is an aryl or heteroaryl; preferably a thiophene or phenyl.
• R° and R p are each independently at each occurrence selected from the group consisting of H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl, C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; with either the proviso that, when one of R° or R p is H, then the other one of R° or R p is not methyl; or with the proviso that the compound is not compound 1 as shown in table 1;
• R° and R p are joined together, forming a cycloalkyl group, cycloalkenyl group, or heterocycloalkyl group optionally substituted with one to four R 1 groups; wherein R 1 is selected from the group consisting of H; halo; cyano; C1-C5 alkyl, preferably C1-C3 alkyl; C1-C3 sulfanyl; C1-C4 alkoxy, preferably C1-C3 alkoxy ; C1-C3 haloalkyl; hydroxyl; oxo; - NRaRb ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; ; (CH 2 ) P NR G R H ; ; (CH 2 ) p OC(0)NRaRb; ; (CH 2 ) p
• Ra and Rb are each independently at each occurence selected from the group consisting of hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxyCl-C6 alkyl, C6-C14 alkyl chain containing one or several of -0-, -C(0)NH-, -NHC(O)-, -N-, or -NHC(0)0- optionally with a terminal -NH 2 or -NH-Boc; C1-C6 alkenyl, substituted C1-C6 alkenyl, C1-C6 alkynyl, substituted C1-C6 alkynyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl; or
• Ra and Rb together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C1-C3 alkyl, benzyl, phenyl, C1-C3 alkoxy or halogen;
• Rc is selected from the group consisting of hydrogen, CI -CIO alkyl, preferably C1-C6 alkyl, CI -CIO alkenyl, preferably C1-C6 alkenyl, CI -CIO alkynyl, preferably C1-C6 alkynyl, C3- C10 cycloalkyl, preferably C3-C7 cycloalkyl, C1-C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl, sulfoxide, aryl, heteroaryl or -NRaRb;
• R G is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl;
• R is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; or
• R G and R H together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C 1 -C 3 alkyl, benzyl, phenyl, C 1 -C 3 alkoxy or halogen;
• X is O, S or N-CN
• Y is NH, 0,-C(0)NH- or a bond
• n is an integer from 0 to 3, preferably 0, 1, 2 or 3
• p is an integer from 0 to 5, preferably 0, 1, 2, 3, 4 or 5.
• R is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ;
• R is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ;
• R" and R are joined together forming a cycloalkyl group, aryl, heteroaryl, or heterocycloalkyl group optionally substituted with one to four R 1 groups;
• R is selected from the group consisting of H; halo; cyano; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; C1-C3 sulfanyl; sulfonyl; sulfoxide; phenyl; aryl; heteroaryl; C1-C5 alkyl; C1-C5 alkenyl; C1-C5 alkynyl; C1-C5 alkyl, alkenyl, or alkynyl substituted with hydroxyl, alkoxy, or -NRaRb; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; -NR G R H ;
• R D is selected from the group consisting of halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; Cl- C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; aryl; heteroaryl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide;
• R is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ; -CH 2 NR M R N ;
• R is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ;
• R E' and R F r are joined together forming a cycloalkyl group, heteroaryl, or heterocycloalkyl group optionally substituted with one to four R 1 groups.
• R G is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl;
• R is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; or
• R G and R H together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C 1 -C 3 alkyl, benzyl, phenyl, C 1 -C 3 alkoxy or halogen;
• R 1 is selected from the group consisting of H; halo; cyano; C1-C5 alkyl, preferably C1-C3 alkyl; C1-C3 sulfanyl; C1-C4 alkoxy, preferably C1-C3 alkoxy ; C1-C3 haloalkyl; hydroxyl; oxo; -NRaRb ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; ; (CH 2 ) P NR G R H ; ; (CH 2 ) p OC(0)NRaRb; ; (CH 2 ) p C(0)NRaRb; C3-C6 cycloalkyl; heterocycloalkyl; aryl; heteroaryl; phenyl;
• R° and R p are each independently at each occurrence selected from the group consisting of H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl, C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; with either the proviso that, when one of R° or R p is H, then the other one of R° or R p is not mefhyl;or with the proviso that the compound is not compound 1 as shown in table 1;
• R° and R p are joined together, forming a cycloalkyl group, cycloalkenyl group, or heterocycloalkyl group optionally substituted with one to four R 1 groups as defined above;
• R M and R N are each independently at each occurence selected from the group consisting of H; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl, phenyl; aryl; heteroaryl; -NR G R H ; - C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; C1-C6 alkyl substituted with hydroxyl, alkoxy, or -NRaRb, phenyl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; or R M and R N are joined together with the N-atom to which they are attached, forming a heterocycloalkyl group; Ra and Rb are each independently at each occurrence selected from the group consisting of hydrogen, C1-C6 alkyl, substituted C1
• Ra and Rb together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C1-C3 alkyl, benzyl, phenyl, C1-C3 alkoxy or halogen;
• Rc is selected from the group consisting of hydrogen, CI -CIO alkyl, preferably C1-C6 alkyl, CI -CIO alkenyl, preferably C1-C6 alkenyl, CI -CIO alkynyl, preferably C1-C6 alkynyl, C3- C10 cycloalkyl, preferably C3-C7 cycloalkyl, C1-C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl, sulfoxide, aryl, heteroaryl or -NRaRb;
• X is O, S or N-CN
• Y is NH, 0,-C(0)NH- or a bond
• n is an integer from 0 to 3, preferably 0, 1, 2 or 3
• p is an integer from 0 to 5, preferably 0, 1, 2, 3, 4 or 5.
• Y is NH
• R C", R D", R E", R F", R O, R P r , and n are as defined above, and wherein
• R Q represents a -substituent which is independently at each occurrence selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; aryl; heteroaryl; -NR G R H ; ; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; (CH 2 ) P NR G R H ; (CH 2 ) p OC(0)NRaRb; (CH 2 ) p C(0)NRaRb;
• R G , R H , Ra, Rb, and Rc have the same meanings defined above; m is an integer from 0 to 2; preferably 0, 1 or 2; n is an integer from 0 to 3 preferably 0, 1, 2 or 3; p is an integer from 0 to 5; preferably 0, 1,2, 3, 4 or 5; q is an integer from 1 to 3; preferably 1, 2 or 3.
• Rc is selected from CI -CIO alkyl, CI -CIO alkenyl, CI -CIO alkynyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl, sulfoxide, aryl, heteroaryl or -NRaRb;
• R M and R N are each independently selected from the group consisting of H; C1-C6 alkyl, C3- C6 cycloalkyl, C1-C3 haloalkyl, phenyl; aryl; heteroaryl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; sulfonyl; sulfoxide; C1-C6 alkyl substituted with hydroxyl, alkoxy, -NRaRb, phenyl, -NR G R H , -C(0)NRaRb, -C(0)Rc, -C(0)ORc, sulfonyl, or sulfoxide; or R M and R N are joined together with the N-atom to which they are attached, forming a heterocycloalkyl group; with R A , R B , R D , R°, R p , R G , R H , Ra, Rb, and Rc
• Rc is selected from CI -CIO alkyl, CI -CIO alkenyl, CI -CIO alkynyl, C3-C10 cycloalkyl, Cl- C3 haloalkyl, -aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl sulfoxide, aryl, heteroaryl or -NRaRb;
• R M and R N are each independently selected from the group consisting of H; C1-C6 alkyl, C3- C6 cycloalkyl, C1-C3 haloalkyl, phenyl; aryl; heteroaryl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; sulfonyl; sulfoxide; C1-C6 alkyl substituted with hydroxyl, alkoxy, -NRaRb, phenyl, -NR G R H , -C(0)NRaRb, -C(0)Rc, -C(0)ORc, sulfonyl or sulfoxide; or R M and R N are joined together with the N-atom to which they are attached, forming a heterocycloalkyl group;
• R Q represents a substituent which is at each occurrence independently selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; aryl; heteroaryl; -NR G R H ; ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) P OH; (CH 2 ) p ORa; (CH 2 ) P NR G R H ; (CH 2 ) p OC(0)NRaRb; (CH 2 ) p C(0)NRaRb; with R A , R B , R D , R G , R H , R°, R p , Ra, Rb, and Rc having the same meanings defined above; m is
• Rc is selected from CI -CIO alkyl, CI -CIO alkenyl, CI -CIO alkynyl, C3-C10 cycloalkyl, Cl- C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl, sulfoxide, aryl, heteroaryl or -NRaRb;
• R M is selected from the group consisting of H; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl, phenyl; aryl; heteroaryl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; C1-C6 alkyl substituted with hydroxyl, alkoxy -NRaRb, phenyl, -NR G R H , - C(0)NRaRb, -C(0)Rc, -C(0)ORc, sulfonyl or sulfoxide;
• R represents a-substituent which is independently at each occurence selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; aryl; heteroaryl; -NR G R H ; ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; (CH 2 ) P NR G R H ; (CH 2 ) p OC(0)NRaRb; (CH 2 ) p C(0)NRaRb; with R A , R B , R D , R G , R H , R°, R p , Ra, Rb, and Rc having the same meanings defined above
• Rc is selected from CI -CIO alkyl, CI -CIO alkenyl, CI -CIO alkynyl, C3-C10 cycloalkyl, Cl- C3 haloalkyl, -aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl, sulfoxide, aryl, heteroaryl or -NRaRb;
• R M is selected from the group consisting of H; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl, phenyl; aryl; heteroaryl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; C1-C6 alkyl substituted with hydroxyl, alkoxy, -NRaRb, phenyl, -NR G R H , - C(0)NRaRb, -C(0)Rc, -C(0)ORc; sulfonyl, or sulfoxide;
• R v and R represents a substituent which is at each occurrence independently selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; aryl; heteroaryl; -NR G R H ; ; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; (CH 2 ) P NR G R H ; (CH 2 ) p OC(0)NRaRb; (CH 2 ) p C(0)NRaRb; with R D , R G , R H , R°, R p , Ra, Rb, and Rc having the same meanings defined above; m is an integer from
• R A is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ;
• R is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ;
• R" and R are joined together forming a cycloalkyl group, aryl, heteroaryl, or heterocycloalkyl group optionally substituted with one to four R 1 groups;
• R D is a substituent which is independently at each occurrence selected from the group consisting of halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; aryl; heteroaryl; NR G R H ; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; sulfonyl; sulfoxide;
• R G is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl;
• R is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; or
• R G and R H together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C 1 -C 3 alkyl, benzyl, phenyl, C 1 -C 3 alkoxy or halogen;
• R 1 is selected from the group consisting of H; halo; cyano; C1-C5 alkyl, preferably C1-C3 alkyl; C1-C3 sulfanyl; C1-C4 alkoxy, preferably C1-C3 alkoxy ; C1-C3 haloalkyl; hydroxyl; oxo; -NRaRb ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; ; (CH 2 ) P NR G R
• R° and R p are each independently at each occurrence selected from the group consisting of H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl, C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; with the proviso that, when one of R° or R p is H, then the other one of R° or R p is not methyl;
• R° and R p are joined together, forming a cycloalkyl group, cycloalkenyl group, or heterocycloalkyl group optionally substituted with one to four R 1 groups as defined above;
• R M and R N are each independently at each occurence selected from the group consisting of H; C1-C6 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl, phenyl; aryl; heteroaryl; -NR G R H ; - C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; C1-C6 alkyl substituted with hydroxyl, alkoxy, or -NRaRb, phenyl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; or R M and R N are joined together with the N-atom to which they are attached, forming a heterocycloalkyl group;
• Ra and Rb are each independently at each occurrence selected from the group consisting of hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, C C 6 alkoxyCl-C6 alkyl, C6-C14 alkyl chain containing one or several of
• Ra and Rb together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C1-C3 alkyl, benzyl, phenyl, C1-C3 alkoxy or halogen;
• Rc is selected from the group consisting of hydrogen, CI -CIO alkyl, preferably C1-C6 alkyl, CI -CIO alkenyl, preferably C1-C6 alkenyl, CI -CIO alkynyl, preferably C1-C6 alkynyl, C3- C0 cycloalkyl, preferably C3-C7 cycloalkyl, C1-C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cacloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or moer of hydroxyl, halo, alkoxy, oxo, sufonyl, sulfoxide, aryl, heteroaryl or -NraRb; i is an integer from 0 to 3, preferably 0, 1, 2 or 3; j is an
• R A is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ;
• R is selected from the group consisting of H; halo; cyano; C1 -C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ; Or R and R are joined together forming a cycloalkyl group, aryl, heteroaryl, or heterocycloalkyl group optionally substituted with one to four R 1 groups;
• R is selected from the group consisting of H; halo; cyano; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; C1-C3 sulfanyl; sulfonyl; sulfoxide; phenyl; aryl; heteroaryl; C1-C5 alkyl; C1-C5 alkenyl; C1-C5 alkynyl; C1-C5 alkyl, alkenyl, or alkynyl substituted with hydroxyl, alkoxy, or -NRaRb; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; -NR G R H ;
• R D is selected from the group consisting of halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; Cl- C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; aryl; heteroaryl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide;
• R is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ; -CH 2 NR M R N ;
• R is selected from the group consisting of H; halo; cyano; C1-C5 alkyl; C3-C6 cycloalkyl; C1-C3 alkoxy; C1-C3 haloalkyl; C1-C3 sulfanyl; phenyl; heteroaryl; -NR G R H ;
• R' and R r are joined together forming a cycloalkyl group, heteroaryl, or heterocycloalkyl group optionally substituted with one to four R 1 groups.
• R G is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl;
• R is selected from the group consisting of H; C1-C6 alkyl; C1-C6 alkoxy;C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; or
• R G and R H together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C 1 -C 3 alkyl, benzyl, phenyl, C 1 -C 3 alkoxy or halogen;
• R ⁇ is selected from the group consisting of H; halo; cyano; C1-C5 alkyl, preferably C1-C3 alkyl; C1-C3 sulfanyl; C1-C4 alkoxy, preferably C1-C3 alkoxy ; C1-C3 haloalkyl; hydroxyl; oxo; -NRaRb ; -C(0)NRaRb; - C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; ; (CH 2 ) P NR G
• R° and R p are each independently at each occurrence selected from the group consisting of H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl, C3-C6 cycloalkyl; heterocycloalkyl; heteroaryl; phenyl; with the proviso that, when one of R° or R p is H, then the other one of R° or R p is not methyl;
• R° and R p are joined together, forming a cycloalkyl group, cycloalkenyl group, or heterocycloalkyl group optionally substituted with one to four R 1 groups;
• R M and R N are each independently selected from the group consisting of H; C1-C6 alkyl, C3- C6 cycloalkyl, C1-C3 haloalkyl, phenyl; aryl; heteroaryl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; - C(0)ORc; sulfonyl; sulfoxide; C1-C6 alkyl substituted with hydroxyl, alkoxy, or -NRaRb, phenyl; -NR G R H ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; or R M and R N are joined together with the N-atom to which they are attached, forming a heterocycloalkyl group;
• R 1 is selected from the group consisting of H; halo; cyano; C1-C5 alkyl, preferably C1-C3 alkyl; C1-C3 sulfanyl; C1-C4 alkoxy, preferably C1-C3 alkoxy ; C1-C3 haloalkyl; hydroxyl; oxo; -NRaRb ; -C(0)NRaRb; -C(0)Rc; -C(0)ORc; sulfonyl; sulfoxide; (CH 2 ) p OH; (CH 2 ) p ORa; ; (CH 2 ) P NR G R H ; ; (CH 2 ) p OC(0)NRaRb; ; (CH 2 ) p C(0)NRaRb; C3-C6 cycloalkyl; heterocycloalkyl; aryl; heteroaryl; phenyl;
• Ra and Rb are each independently at each occurrence selected from the group consisting of hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl; C1-C6 alkoxyCl-C6 alkyl, C6-C14 alkyl chain containing one or several of -0-, -C(0)NH-, -NHC(O)-, -N-, or -NHC(0)0- optionally with a terminal NH 2 or -NH-Boc; C1-C6 alkenyl, substituted C1-C6 alkenyl, C1-C6 alkynyl, substituted C1-C6 alkynyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl; or
• Ra and Rb together with the nitrogen atom to which they are bonded, form a 4- to 10- membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C1-C3 alkyl, benzyl, phenyl, C1-C3 alkoxy or halogen;
• Rc is selected from the group consisting of hydrogen, CI -CIO alkyl, preferably C1-C6 alkyl, CI -CIO alkenyl, preferably C1-C6 alkenyl, CI -CIO alkynyl, preferably C1-C6 alkynyl, C3- C10 cycloalkyl, preferably C3-C7 cycloalkyl, C1-C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycl
• X is O, S or N-CN
• Y is NH, 0,-C(0)NH- or a bond
• n is an integer from 0 to 3, preferably 0, 1, 2 or 3
• p is an integer from 0 to 5, preferably 0, 1, 2, 3, 4 or 5.
• Y is NH
• the invention also relates to pharmaceutically acceptable salts of the aforementioned compounds of formulae I, la- Hi.
• the present invention is also directed to compounds according to Formula II:
• V is an aryl or heteroaryl selected from the group consisting of
• R a is, independently at each occurrence, selected from the group consisting of H, C1-C4 alkyl, C1-C3 alkoxy, halo,such as CI or F, cyano, -C(0)NRR, CF 3 , OCF 3 , hydroxyl, N(CH 3 ) 2 , N0 2 , morpholinyl, -NHC(O) C1-C3 alkyl, C(0)(0) C1-C4 alkyl, NH 2 C(0)-, NH 2 S(0) 2 -, CH 2 OH, CH 2 -morpholinyl; with R being independently at each occurrence selected from the group consisting of H, C1-C4 alkyl, C3-C7 cycloalkyl and CF 3 ;
• R b is selected from the group consisting of H, C1-C4 alkyl, C1-C3 alkoxy, halo, CF 3 , OCF 3 , cyano;
• X is selected from the group consisting of -C(0)NR-, -NR-C(O)-, -NRC(0)NR-, -C(0)NCH 3 -, NCH 3 -C(0)-, -NR-, -RNHR-, -RNHC(0)NR-, -S(0) 2 NH-; -C(O)-; with R being independently at each occurrence selected from the group consisting of H, C1-C4 alkyl, C3- C7 cycloalkyl and CF 3 ;
• Y is selected from groups consisting of
• n is independently at each occurrence an integer from 0 to 4, preferably 0, 1, 2, 3 or 4;
• k is an integer from 1 to 3, preferably 0, 1, 2 or 3;
• n is an integer from 0 to 3, preferably 0, 1, 2 or 3;
• Z is selected from the group consisting of CH 2
• the invention also relates to pharmaceutically acceptable salts of these compounds according to formula II. It should be noted that, as far as product protection is concerned the present invention does not encompass the compound designated "1001" in table 2 as shown further below.
• One embodiment relates to compounds according to Formula II, wherein
• X is -C(0)NR-, with R being selected from the group consisting of H, C1-C4 alkyl, C3-C7 cycloalkyl and CF3; and Y is -(CH 2 ) m -, m being 0 to 4,preferably 0, 1, 2, 3 or 4.
• One embodiment relates to compounds according to Formula II wherein X is -NR-C(O)-, with R being selected from the group consisting of H, C1-C4 alkyl, C3-C7 cycloalkyl and CF3; and Y is -(CH 2 ) m -, m being 0 to 4, preferably 0, 1, 2, 3 or 4.
• X is -C(0)NR-, with R being selected from the group consisting of H, C1-C4 alkyl, C3-C7 cycloalkyl, CF 3 ; Y is -(CH 2 ) m -, m being 0 to 4; n is 1 and Z is
• One embodiment relates to compounds according to Formula II wherein X is -NR-C(O)-, with R being selected from the group consisting of H, C1-C4 alkyl, C3-C7 cycloalkyl, CF 3 ; Y is -(CH 2 ) m -, with m being 0 to 4; n being 1; Z being
• the compound according to the present invention is for use in the treatment of a viral disease, preferably HCV.
• said HCV is HCV genotype 1, 2, 3, 4, 5, 6, 7, including subtypes, preferably genotypes and subtypes la, lb, 2a, 2b, 3a, 4a, 5a, 6a and/or 7a, more preferably la, lb, 2a, 2b and/or 3a.
• the compound according to the present invention has one of the formulae 2-374, as shown in Table 1 and/or Example 1, as shown further below, or a pharmaceutically acceptable salts thereof, preferably having one of the formulae 2-4, 7, 12, 14, 18-22, 24-44, 46-48, 51-54, 56-57, 59-63, 65-76, 78-82, 87, 91, 93-94, 96-99, 101-103, 106-108, 110-119, 121-200, 203-222, 224-229, 231-245, 247-256, 258-320, 322-351, 354-361, 363-373, as indicated in Table 1 more preferably having one of the formulae 14, 19, 21, 27, 110-119, 121, 167, 316 as indicated in Tables 1, 3, 4 or 5; or a pharmaceutically acceptable salt thereof.
• the compound according to the present invention has one of the formulae 1002-1159, as shown in Table 2 and/or Example 1, as shown further below, or a pharmaceutically acceptable salt thereof, preferably having one of the formulae 1003, 1005, 1012-1013, 1015-1016, 1018-1023, 1027-1028, 1032, 1045-1046, 1049, 1052, 1060, 1065, 1067-1069, 1073, 1075-1076, 1078-1083, 1085-1088, 1090-1102, 1104-1108, 1110-1119, 1121-1126, 1130-1137, 1139, 1141, 1145-1147, 1149-1150, 1152-1159 as indicated in Table 2 more preferably having one of the formulae 1013, 1019, 1022, 1152 as indicated in Tables 2-3; or a pharmaceutically acceptable salt thereof.
• the present invention relates to a composition
• a composition comprising a compound as defined above and a pharmaceutically acceptable carrier, excipient or diluent.
• the composition according to the present invention is for use in the treatment of a viral disease, preferably HCV.
• HCV is HCV genotype 1, 2, 3, 4, 5, 6 or 7, including subtypes, preferably genotypes and subtypes la, lb, 2a, 2b, 3a, 4a, 5a, 6a and/or 7a, more preferably la, lb, 2a, 2b and/or3a.
• said treatment comprises administering a suitable amount of a compound as defined above or of a composition as defined above to a patient in need thereof suffering from a viral disease, preferably HCV.
• the present invention relates to a method of treatment of a viral disease, said disease preferably being HCV.
• Said method comprising the administration of a suitable amount of a compound as defined above or of a composition as defined above to a patient in need thereof, suffering from a viral disease, said viral disease preferably being HCV.
• said HCV is HCV genotype 1, 2, 3, 4, 5, 6 or 7, including subtypes, preferably genotype la, lb, 2a, 2b, 3a, 4a, 5a, 6a and/or 7a, more preferably la, lb, 2a, 2b and/or 3a.
• said suitable amount is an amount in the range of 0.01 mg/kg body weight to 1 g/kg body weight of said patient.
• said patient is a patient suffering from a viral disease, preferably HCV.
• the present invention also relates to pharmaceutically acceptable salts of the compounds according to the present invention, for use in the treatment of a viral disease, preferably HCV.
• said compound has an inhibitory activity on viral infection, preferably HCV, at a concentration of said compound between 0.0001-50 uM, particularly preferably having an EC 50 of less than 1 uM.
• the present invention relates to compounds for use in the treatment of a viral disease, e.g. HCV, according to the present invention, said compound preferably having one of the formulae 1-374 and/or 1001-1159, as shown in Tables 1 and 2 and Example 1, preferably having one of the formulae 1-4, 7, 12, 14, 18-22, 24-44, 46-48, 51-54, 56-57, 59-63, 65-76, 78-82, 87, 91, 93-94, 96-99, 101-103, 106-108, 110-119, 121-200, 203-222, -224-229, 231-245, 247-256, 258-320, 322-351, 354-361, 363-373, 1001, 1003, 1005, 1012-1013, 1015- 1016, 1018-1023, 1027-1028, 1032, 1045-1046, 1049, 1052, 1060, 1065, 1067-1069, 1073, 1075-1076, 1078-1083, 1085-1088,
• the compounds as defined above have an inhibitory activity on viral infection, preferably an HCV infection at a concentration of said compound between 0.0001-50 uM, particularly preferably having an EC 50 of less than 1 uM.
• the present invention relates to a composition
• a composition comprising a compound according to the present invention and a pharmaceutically acceptable carrier, excipient or diluent, for use in the treatment of a viral disease, preferably HCV, HCV being as defined above.
• said treatment comprises administering a suitable amount of a compound or of a composition as defined above to a patient in need thereof, suffering from a viral disease, preferably HCV, HCV being as defined above.
• a viral disease preferably HCV, HCV being as defined above.
• the present invention relates to a compound that competitively inhibits the specific binding of a compound according to the present invention as defined above.
• the present invention relates to method of treatment of a viral disease, e.g. HCV, said method comprising the administration of a suitable amount of a compound as just defined, i.e. a compound that competitively inhibits the specific binding of a compound according to the present invention to a patient in need thereof.
• a viral disease e.g. HCV
• Such compound that competitively inhibits the specific binding of a compound according to the present invention is herein also sometimes referred to as a "competitively inhibitory compound”.
• such patient is a patient suffering from a viral disease, preferably HCV.
• the present invention also relates to a composition, preferably a pharmaceutical composition, comprising a compound according to the present invention, as defined above, further comprising at least one antiviral compound and, optionally, a pharmaceutically acceptable carrier, excipient or diluent.
• This composition is also sometimes herein referred to as a "combination composition”.
• said at least one antiviral compound is selected from interferon-alpha, ribavirin, direct acting antivirals, such as telaprevir, boceprevir, sofosbuvir, daclatasvir, NS5A-inhibitors, non-nucleoside inhibitors of HCV-RNA-dependent RNA polymerase (RdRp).
• such combination composition is for use in the treatment of a viral disease, preferably, HCV, more preferably, HCV genotype 1, 2, 3, 4, 5, 6 or 7, including subtypes, preferably genotype la, lb, 2a, 2b, 3a, 4a, 5a, 6a and/or 7a, more preferably la, lb, 2a, 2b and/or 3a.
• HCV HCV genotype 1, 2, 3, 4, 5, 6 or 7, including subtypes, preferably genotype la, lb, 2a, 2b, 3a, 4a, 5a, 6a and/or 7a, more preferably la, lb, 2a, 2b and/or 3a.
• the compound according to the present invention has one of the formulae 1-374, as shown in Table 1 and/or Example 1, as shown further below, or pharmaceutically acceptable salts thereof, preferably having one of the formulae 1-4, 7, 12, 14, 18-22, 24-44, 46-48, 51-54, 56-57, 59-63, 65-76, 78-82, 87, 91, 93-94, 96-99, 101-103, 106- 108, 110-119, 121-200, 203-222, 224-229, 231-245, 247-256, 258-320, 322-351, 354-361, 363-373, as indicated in Table 1 more preferably having one of the formulae 14, 19, 21, 27, 110-119, 121, 167, 316 as indicated in Tables 1, 3, 4 or 5; or a pharmaceutically acceptable salt thereof.
• the compound according to the present invention has one of the formulae 1001-1163, as shown in Table 2 and/or Example 1, as shown further below, or a pharmaceutically acceptable salt thereof, preferably having one of the formula 1001, 1003, 1005, 1012-1013, 1015-1016, 1018-1023, 1027-1028, 1032, 1045-1046, 1049, 1052, 1060, 1065, 1067-1069, 1073, 1075-1076, 1078-1083, 1085-1088, 1090-1102, 1104- 1108, 1110-1119, 1121-1126, 1130-1137, 1139, 1141, 1145-1147, 1149-1150, 1152-1159as indicated in Table 2 more preferably having one of the formulae 1013, 1019, 1022, 1152 as indicated in Tables 2-3; or pharmaceutically acceptable salt thereof.
• a viral disease preferably HCV, more preferably HCV genotype 1, 2, 3, 4, 5, 6 or 7, including subtypes, preferably genotype la, lb, 2a, 2b, 3a, 4a, 5a, 6a and/or 7a, more preferably la, lb, 2a, 2b and/or 3a.
• EC 50 refers to the half-maximal effective concentration of a compound with respect to a given activity, for example, an inhibition of infection of a cell with a pathogen, e.g. a virus.
• the EC50 of a graded dose response curve therefore represents the concentration of a compound where 50% of its maximal effect is observed.
• One example of an EC 50 is the half- maximal inhibitory concentration of a compound for the infection of cell with HCV.
• Examples of pharmaceutically acceptable addition salts include, without limitation, the nontoxic inorganic and organic acid addition salts such as the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulfonate derived from benzensulfonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enanthate derived from enanthic acid, the formate derived from formic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from mal
• acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt, for use inthetreatment of an inflammatory disease.
• the compounds of the invention are used in their respective free base form, for use in the treatment of an inflammatory disease, according to the present invention.
• Metal salts of a chemical compound of the invention include alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.
• the chemical compounds of the invention may be provided in unsolvated or solvated forms together with a pharmaceutically acceptable solvent(s) such as water, ethanol, and the like.
• Solvated forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of this invention.
• the compounds of the invention may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
• Such salts of the compounds of the invention may be anhydrous or solvated.
• the invention provides medicaments comprising a compound useable according to the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers therefor, and, optionally, other therapeutic and/or prophylactic ingredients.
• the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
• a medicament of the invention may be those suitable for oral, rectal, bronchial, nasal, topical, buccal, sub-lingual, transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
• sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
• the compounds useable according to the invention may thus be placed into the form of medicament and unit dosages thereof.
• Such forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
• Such medicament and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
• compositions useable according to the invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound(s) useable according to the invention or a pharmaceutically acceptable salt of a compound(s) useable according to the invention.
• pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
• a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
• the carrier is a finely divided solid which is in a mixture with the finely divided active component.
• the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
• Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
• the term "preparation” is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
• cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
• a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
• the active component is dispersed homogeneously therein, as by stirring.
• the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
• Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
• Liquid preparations include solutions, suspensions, and emulsions, for example, water or water- propylene glycol solutions.
• parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
• the chemical compounds according to the present invention may thus be formulated for parenteral administration (e.g. by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative.
• the compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
• the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
• Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
• Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
• solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
• liquid forms include solutions, suspensions, and emulsions.
• These preparations may contain, in addition to the active component, colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
• the medicament is applied topically or systemically or via a combination of the two routes.
• the compounds of the present invention may, in one embodiment, be administered in a formulation containing 0,001% to 70% per weight of the compound, preferably between 0,01% to 70% per weight of the compound, even more preferred between 0,1% and 70% per weight of the compound.
• a suitable amount of compound administered is in the range of 0.01 mg/kg body weight to 1 g/kg body weight.
• compositions suitable for administration also include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerol or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
• lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth
• pastilles comprising the active ingredient in an inert base such as gelatin and glycerol or sucrose and acacia
• mouthwashes comprising the active ingredient in a suitable liquid carrier.
• Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
• the compositions may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.
• Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
• a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
• CFC chlorofluorocarbon
• the aerosol may conveniently also contain a surfactant such as lecithin.
• the dose of drug may be controlled by provision of a metered valve.
• the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
• a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
• PVP polyvinylpyrrolidone
• the powder carrier will form a gel in the nasal cavity.
• the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
• the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micronization.
• compositions adapted to give sustained release of the active ingredient may be employed.
• the pharmaceutical preparations are preferably in unit dosage forms.
• the preparation is subdivided into unit doses containing appropriate quantities of the active component.
• the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
• the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form. Tablets or capsules for oral administration and liquids for intravenous administration and continuous infusion are preferred compositions.
• Table 1 summarizes anti-HCVcc genotype 1/2 activity for Formula I Series.
• Table 2 summarizes anti-HCVcc genotype 1/2 activity for Formula II Series.
• Table 3 summarizes anti-HCV cross-genotypic activity for a respresentative of Formula I and II Series.
• Table 4 summarizes the drug combination evaluation for a representative of Formula I Series in the HCV genotype 2 infectious system.
• Table 5 summarizes the drug combination evaluation for a representative of Formula I Series in the HCV genotype 1/2 chimeric infectious system.
• the compounds according to Formula I are prepared using conventional organic syntheses. Suitable synthetic routes are depicted below in the following general reaction schemes. In the following, sometimes reference is made to compounds according to the present invention as “TU-” followed by a letter, such as “A”, “B” etc. "TU” is meant to abbreviate “thiophene urea” from which these compounds are derived. "A”, “B” etc. is just a numbering. However, it should be noted that the designation “TU” or “thiophene urea” when used in conjunction with the designation of the compounds according to the present invention is not meant to be construed in a limiting manner. The compounds according to the present invention are intended to be limited only by the various claims appended hereto, and in particular by the structures and formulae indicated therein.
• reaction mixture was stirred for 30 min at room temperature and heated to 80 °C for 5 h.
• Step - 1 Step - 2 overnight 1 h
• Step - 1 Step - 2 Step - 3
• Step - 3> The procedure 1 - 25 was followed by procedure of General procedure 1 (Step - 5) (36%, yellow oil).
• Step - 2 The procedure 1 - 26 was followed by procedure of General procedure 14 (Step - 2) (61 , ivory solid).
• Step - 3 Step - 4
• Step - 1 Step - 2
• Step - 1 Step - 2
• Step - 3> The procedure 1 - 38 was followed by procedure of General procedure 1 (Step - 5) (47%, colorless oil).
• Step - 39 was followed by procedure of General procedure 21 (Step - 2) (55%, colorless oil).
• Step - 1 Step - 2
• Step - 3 Step - 4 overnight
• Step - 1 Step - 2
• Step - 3 Step - 4
• Step - 2 The procedure 1 - 53 was followed by procedure of General procedure 21 (Step - 2) (51%, colorless oil).
• Step - 1 Step - 2
• Step - 1 Ste -2
• Step - 3 Step - 4 Step - 5
• Step - 1 Ste - 2 Step - 3
• Step - 1 O Step - 2
• Step - 1 Step - 2
• Step - 1 Step - 2
• Step 2) the synthesis of PI - 2
• Step 4) the synthesis of DP - A
• DI - 4 and NaOH (10 eq) were added to EtOH/H 2 0 (10: 1) solution.
• the mixture was heated to reflux for 3 h.
• the mixture was cooled to room temperature and evaporated.
• the mixture was dissolved in water and slowly acidified with 10% aq. HC1 and extracted with CH 2 C1 2 .
• the extract was dried over MgS0 4 , filtered, and concentrated to afford DI - 5 (90-92%) as ivory solid.
• PI - 6 (0.09 g, 0.33 mmol) was added NaOH (0.13 g, 3.30 mmol) in EtOH/H 2 0 (10: 1) solution. The mixture was heated to reflux for 3 h. The mixture was cooled to room temperature and evaporated. The mixture was dissolved in water and slowly acidified with 10% aq. HC1 and extracted with CH 2 CI 2 . The extract was dried over MgS0 4 , filtered, and concentrated to afford PI - 7 (0.08 g, 94%) as white solid.
• Step 3 The synthesis of PP - C A solution of DI - 7 (0.05 g, 0.21 mmol), EDC (0.05 g, 0.25 mmol), Et 3 N (0.06 mL, 0.41 mmol) and HOBt (0.03 g, 0.25 mmol). After stirring at room temperature for 5 h, the mixture was partitioned between CH 2 CI 2 (10 mL) and water (10 mL). The organic layer was collected and concentrated in vacuo. Purification by column chromatography (30% MeOH in CH 2 CI 2 ) to give DP - C (12-35%).
• Naive Huh-7.5 target cells were plated at 2400 cells/well in 25 ⁇ ⁇ of culture media in 384- well plates (Greiner bio-one, ⁇ clear black). After overnight incubation, compounds serially diluted in 10 ⁇ ⁇ of cell culture media were added. After 2 h compound treatment, cells were inoculated with 40 ⁇ ⁇ of genotype 1/2 chimeric cell culture derived HCV (HCVcc) which express structural proteins of an HCV genotype la isolate (TN accession number EF621489) and non- structural proteins of HCV genotype 2a (JFH-1) with nano-luciferase reporter.
• HCVcc genotype 1/2 chimeric cell culture derived HCV
• Nano-luciferase activity (Nano-GloTM, Promega) and cellular ATP (Cell titer- GloTM, Promega) were measured as a marker for HCV replication and cytotoxicity, respectively.
• EC 50 and CC 50 were calculated by non-linear regression analyzing using GraphPad Prism (GraphPad Software).
• Pan-genotypic activity test using chimeric HCVcc assay In order to evaluate cross-genotypic antiviral activity against various HCV genotypes, Formulas I and II were tested using chimeric HCVcc as described above. HCV chimeras expressing the structural proteins of HCV genotype lb (J4), 2a (J6), 2b (J8), 3a (S52), 4a (ED43), 5a (SA13), 6a (HK6a) or 7a (QC69), followed by HCV genotype 2a (JFH-1) derived non- structural proteins responsible for viral RNA replication and Renilla luciferase reporter gene were used to monitor viral replication. Formulas I and II efficiently inhibit all tested HCV subtypes and genotypes (Table 3).
• Drug combination studies may be increasingly valuable for pre-clinical pharmaceutical research.
• chronically HCV infected patients may be treated with a combination of viral inhibitors to reduce treatment period, increase sustained viral response rates, prevent viral drug resistance, etc.
• a combination is synergistic or additive, lower drug doses can be used to achieve the same or even better efficacy with lower toxicity can be evaluated in vitro by combining multiple inhibitors at various concentrations.
• drug combination studies are also being instrumentalized to rule out that new clinical compounds will not decrease the effectiveness of standard therapy, thereby avoiding potentially harmful consequences for patients.
• Friebe, R, et al. Sequences in the 5' nontranslated region of hepatitis C virus required or RNA replication. J Virol, 2001. 75(24): p. 12047-57.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Virology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Molecular Biology (AREA)
• Gastroenterology & Hepatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Pyrrole Compounds (AREA)
• Hydrogenated Pyridines (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=52824259

Family Applications (1)

Country Status (10)

Cited By (1)

Citations (7)

Family Cites Families (3)

• 2015
  • 2015-04-17 JP JP2017505723A patent/JP6527580B2/ja not_active Expired - Fee Related
  • 2015-04-17 ES ES15715776T patent/ES2738693T3/es active Active
  • 2015-04-17 CN CN201580032657.9A patent/CN106470974B/zh not_active Expired - Fee Related
  • 2015-04-17 EP EP15715776.9A patent/EP3131890B1/en active Active
  • 2015-04-17 WO PCT/EP2015/058421 patent/WO2015158908A1/en active Application Filing
  • 2015-04-17 US US15/304,612 patent/US9809602B2/en active Active
  • 2015-04-17 CA CA2946062A patent/CA2946062C/en active Active
  • 2015-04-17 PL PL15715776T patent/PL3131890T3/pl unknown
  • 2015-04-17 TR TR2019/10305T patent/TR201910305T4/tr unknown
  • 2015-04-17 KR KR1020167031006A patent/KR102346605B1/ko active IP Right Grant

Patent Citations (7)

Non-Patent Citations (21)

Also Published As

Similar Documents

Legal Events